Oral anticoagulation in clinical practice

Journal, Indian Academy of Clinical Medicine

Volumn 6, Issue 1, 2005, Pages 53-66

  Gogna, Arun ^a   Arun, Sandeep ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

Bleeding; INR monitoring; Oral anticoagulation; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMIODARONE; ANDROGEN; ANTICOAGULANT AGENT; CHLORAMPHENICOL; CIMETIDINE; CLOFIBRATE; COTRIMOXAZOLE; DIPYRIDAMOLE; DISULFIRAM; ERYTHROMYCIN; FLUCONAZOLE; FLUOXETINE; GLUCAGON; HEPARIN; INDOMETACIN; METRONIDAZOLE; PARACETAMOL; PHENFORMIN; PHENYLBUTAZONE; PHENYTOIN; PHYTOMENADIONE; PROBENECID; QUINIDINE; SULFINPYRAZONE; TAMOXIFEN; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

BLEEDING; CEREBROVASCULAR ACCIDENT; CHONDRODYSPLASIA PUNCTATA; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; EMBOLISM; ENDOCARDITIS; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MENTAL DEFICIENCY; META ANALYSIS; MITRAL VALVE DISEASE; OPTIC NERVE ATROPHY; REVIEW; SKIN NECROSIS; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

EID: 27944443685     PISSN: 09723560     EISSN: 09723560     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Schulman S. Oral anticoagulation. In: Beutler E, Lichtman MA, Coller Bs, Kipps IJ, Seligsohn U, eds. Williams hematology. 6th ed. New York: McGraw-Hill, 2001; 1777-92.
2. Stein PD, Alpert JS, Busscy HI et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001; 119 (Suppl):220S-227S.
3. (Erratum, Chest 2001; 120:1044).
4. Gokhle - Barwolf C, Acar J, Oakley C et al. Guidelines for prevention of thromboembolic events in valvular heart disease. Eur Heart J 1995; 16:1320-30.
5. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89:635-41.
6. Heras M, Chesebro JH, Fuster V et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995; 25:1111-9.
7. Albers GW, Dalen JE, Laupacis A et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119 (Suppl):194S-206S.
8. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the management of patients with atrial fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38:1231-66.
9. Koefoed BG Peterson P. Oral anticoagulation in nonvalvular fibrillation. J Intern Med 1999; 245:375-81.
10. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-57.
11. (Erratum, Arch Intern Med 1994; 154:2254).
12. Caims JA, Theroux P, Lewis HD Jr et al. Antithrombotic agents in coronary artery disease. Chest 2001; 119(Suppl):228S-52S.
13. (Erratum, Chest 2001; 120:427).
14. Smith P. Oral anticoagulants are effective long-term after acute myocardial infraction. J Intern Med 1999; 245:383-7.
15. Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infraction. N Engl J Med 2002; 347:969-74.
16. Pauker SG, Eckman MH, Riff J. Antithrombotic therapy in valvular heart disease. Chest 2001; 119(Suppl):207S-19S.
17. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342:1255-62.
18. Becker RC. Antithrombotic therapy after myocardial infraction. N Engl J Med 2002; 347:1019-22.
19. Hyers, TM, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119 (Suppl):176S-93S.
20. Iagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulation treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2:515-8.
21. Levine MN, Raskob G, Landefeld S, Kearon C. Haemorrhagic complications of anticoagulation treatment Chest 2001; 119 (Suppl):108S-21S.
22. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy: Am J Med 1989; 87:144-52.
23. Mok CK, Boey J, Wang R et al. Warfarin versus dipyridamole aspirin and pentoxiphyl line aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomised clinical trial: Circulation 1985; 72:1059-63.
24. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta analysis. Ann Intern Med 1999; 131:492-501.
25. Massel D, Little SH, Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valve: a meta analysis. J Am Coll Cardiol 2001; 37:569-78.
26. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to Warfarin Therapy. AHA/ACC Scientific statement. Circulation 2003; 107:1692-1711.
27. Gallus A, Jackman J, Tllett J et al. Safety and efficacy of warfarin started early after submassive venous thrombosis of pulmonary embolism. Lancet 1986; 2:1293-6.
28. Schulman S, Lockner D, Bergstrom K, Blomback M. Intensive initial oral anticoagulation and shorter heparin treatment in deep vein thrombosis. Thromb Haemost 1984; 52:276-80.
29. Harrison L, Johnston M, Massicotte MP et al. Comparison of 5 - mg and 10 - mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126:133-6.
30. Jillella AP, Lutcher CL. Reinstituting warfarin in patients who develop warfarin skin necrosis. Am J Hematol 1996; 52:117-9.
31. Ridker PM, Goldhaber SZ, Danielson E et al. Long-term intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348:1425-1434.
32. Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332:993-7.
33. Schulman S, Duration of Anticoagulation Study Group. The effect of the duration of anticoagulation and other risk factors on the recurrence of venous thromboembolisms. Wien Med Wochendchr 1999; 149:66-9.
34. Hutten BA, Prins MH, Gent M et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18:3078-83.
35. Schulman S, Granqvist S, Holmstrom M et al. He duration of oral anticoagulation therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336:393-8.
36. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia. Thromb haemost 1996; 76:651-62.
37. Van den Belt AGM, Sanson B-J, Simioni P et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157:2227-32.
38. Procare Group. Comparison of thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: retrospective analysis from the Procare Study. Blood Coagul Fibrinolysis 2000; 11:511-8.
39. De Stefano V, Martinelli I, Mannucci PM et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341:801-6.
40. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345:1593-600.
41. Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343:457-62.
42. Karlson B, Leijd B, Hellstrom K. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand 1986; 220:347-50.
43. Pedersen FM, Hamberg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin. Induced anticoagulation. J Intern Med 1991; 229:517-20.
44. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs; a systematic review. Drugs 2001; 61: 2163-75.
45. Crowther MA, Julian J, McCarty D et al. Treatment of warfarin associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356:1551-3.
46. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1. In reversing excessive oral anticoagulation. Am J Cardiol 1999; 83:286-8, A6-7.
47. Makris M, Greaves M, Phillips WS et al. Preston FE. Emergency oral anticoagulation reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on corrections of the coagulopathy Thromb haemost 1997; 77:477-80.
48. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336:1506-11.
49. Ramstrom G, Sindet-Pedersen S, Hall G et al. Prevention of post surgical bleeding in oral surgery using tran-examic acid without dose modification of oral anticoagulants. J Oral Maxillofac Surg 1993; 51:1211-6.
50. Vigano 'D'Angelo S, Tsoureli E, Crippa L, Tomassini L et al. Prevalence of haemorrhagic and thrombotic complications in patients requiring oral anticoagulation and submitted to elective surgery: a study of 197 consecutive patients. Thromb Res 1998; 91(Suppl 1):S100 abstract.
51. Reimold SC, Rutherford JD. Valvular heart disease in pregnancy. N Engl J Med 2003; 349:52-9.
52. J Sri Mannarayana, Verma RS, Satheish S et al. Prevalence of left atrial thrombus in rheumatic mitral stenosis with atrial fibrillation and its response to anticoagulation. A transesophageal echo-cardiographic study. Indian Heart J2003; 55:358-61.
53. Mcgray TFJ, Gottilieb RS, Morganroth J et al. Anticoagulation in cardiac catheterisation. Am Heart J 1992; 123:1445-51.
54. Gorter JW. Anticoagulation after stroke: patterns and risk factor. Neurology 1999; 53:1319.
55. Kaye D (ed). Infective endocarditis 2nd ed. New York Raven, 1992.
56. Ryan TJ, Antman EM, Brooks NH et al. 1999 Update:ACC/ AHA guidelines for the management of patients with acute myocardial infraction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infraction). Circulation 1999; 100:1016-30.